As cell-containing therapies move toward broader commercialization, manufacturers are updating particulate control and inspection strategies to meet evolving regulatory expectations. Coverage describes how CMC teams are addressing practical limits in visually inspecting cell products, which are often stored in opaque bags and cannot be terminally sterilized. Industry specialists cite new workflows that run particulate sampling in formulation buffers without cells to generate measurable reference data, then extrapolate to final cell-containing batches. The guidance also references compendial frameworks such as USP <790> (visible particles), USP <1790> (visual inspection), and USP <788> (sub-visible particles) as part of how quality teams justify controls. For biotech developers and CDMOs, the update is a reminder that commercialization is increasingly constrained by manufacturing verification requirements as much as by clinical efficacy. It also suggests that regulators may scrutinize particulate risk more closely for cell-based products administered by different routes, pushing companies toward route-specific testing plans.